Hemostemix Inc HMTXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.04
- Day Range
- $0.04–0.04
- 52-Week Range
- $0.04–0.14
- Bid/Ask
- $0.02 / $0.04
- Market Cap
- $3.33 Mil
- Volume/Avg
- 58,000 / 11,420
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.hemostemix.com
Valuation
|
Metric
|
HMTXF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
HMTXF
Financial Strength
|
Metric
|
HMTXF
|
|---|---|
Quick Ratio | 0.17 |
Current Ratio | 0.25 |
Interest Coverage | −4.99 |
Quick Ratio
HMTXF
Profitability
|
Metric
|
HMTXF
|
|---|---|
Return on Assets (Normalized) | −506.02% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
HMTXF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rjtfqdkd | Pwb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vhdhlmygg | Ryrfrt | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dwqyylst | Frjlmng | $97.8 Bil | |
MRNA
| Moderna Inc | Txhvlrw | Mqyf | $41.3 Bil | |
ARGX
| argenx SE ADR | Sqkzlhfd | Zvvvn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jxdfgkjf | Rhjc | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gnqmnpg | Yqhhzx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Frncvqcg | Pstjp | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pnymbbmny | Kkhbkj | $12.5 Bil | |
INCY
| Incyte Corp | Ryyqnqqj | Tdqczws | $11.6 Bil |